Anthropic's S-1 filing says Claude can accelerate drug discovery and biology research, making life sciences central to the AI company's IPO pitch.

Anthropic reported third-quarter revenue of $16.8 billion. That was up 45% from the second quarter.

Michael Burry sees turnaround potential for shares of Build-A-Bear Workshop. The stock has cratered by more than 50% in 2026.

Google shares fell 10% in premarket trade. If the fall holds, it will be the biggest negative stock reaction to earnings since it went public in 2004.

SpaceX's outreach to retail investors ended up being a defining piece of its blockbuster IPO in June. Anthropic could follow suit.

A head-to-head trial showed that at the highest dose, retatrutide produced average weight loss of 44 to 47 pounds, compared with 21 pounds for Ozempic. Eli Lilly expects to submit retatrutide to the FDA for approval in early 2027.

Anthropic's multichip strategy could weaken Nvidia's pricing power over time, though analysts say switching between AI chips remains difficult.

Anthropic's post-IPO lockup structure is unusual, with employees and founders able to sell at points beginning on the day the stock starts trading.

Michael Burry said Anthropic's revenue growth is slowing. Third-quarter revenue was about 86 times the level recorded in the fourth quarter of 2024. Quarter-over-quarter growth cooled to roughly 46% from 144%.